PMID- 30127918
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 3
DP  - 2018 Sep
TI  - The impact of exogenous CO releasing molecule CORM-2 on inflammation and 
      signaling of orthotopic lung cancer.
PG  - 3223-3230
LID - 10.3892/ol.2018.9022 [doi]
AB  - The present study aimed to evaluate the therapeutic effect of CO-releasing 
      molecule-2 (CORM-2) in an established mouse orthotopic lung cancer model and 
      investigate the underlying mechanism associated with inflammation pathway. A 
      total of 80 mice were randomly divided into two groups with 20 serving as a 
      normal control and 60 used for the orthotopic lung cancer model. The tumor group 
      was either untreated, or administrated with DMSO or CORM-2. The mice were 
      sacrificed at day 7 and 14 post-treatment, and the body weight, and thymus and 
      spleen indices were determined. Pathological analysis was performed with 
      hematoxylin and eosin (HE) staining. Serous inflammatory factors were measured 
      using an ELISA. The expression levels of eukaryotic translation initiation factor 
      4E, p70S6K and toll-like receptor-4 (TLR4) were quantified by reverse 
      transcription-polymerase chain reaction. The effects of CORM-2 on the 
      phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of 
      rapamycin (mTOR), TLR4/nuclear factor (NF)-kappaB signaling pathways were determined 
      by western blotting. The body weight increased over time in the control group, 
      while it significantly declined in tumor-bearing mice (P<0.05). CORM-2 treatment 
      significantly increased body weight in comparison with the model and DSMO 
      treatment groups (P<0.05). The thymus and spleen indices both reduced in the 
      model and DMSO treatment groups, which was significantly rescued with CORM-2 
      administration (P<0.05). The HE staining results demonstrated few nodule 
      formations, fibrous hyperplasia and extensive necrosis, which suggested overt 
      inhibitory effects against cancer of CORM-2. The serous contents of tumor 
      necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the CORM-2 group was 
      significantly lower compared with that in the model and DMSO groups (P<0.05). The 
      ratio of phosphorylated (p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR, 
      p-NF-kappaB-p65/NF-kappaB-p65 and expression of TLR4 significantly decreased in the 
      CORM-2 group compared with the model and DMSO groups (P<0.05). To the best of our 
      knowledge, the data in the present study demonstrated in vivo for the first time, 
      the therapeutic potential of the CORM complex, which is associated with 
      suppression of inflammation and general protein synthesis.
FAU - Shao, Li
AU  - Shao L
AD  - Department of Integrated Traditional Chinese and Western Medicine, The Affiliated 
      Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. 
      China.
FAU - Liu, Congyang
AU  - Liu C
AD  - Department of Integrated Traditional Chinese and Western Medicine, The Affiliated 
      Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. 
      China.
FAU - Wang, Shuhua
AU  - Wang S
AD  - Department of Information, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong 264000, P.R. China.
FAU - Liu, Jiannan
AU  - Liu J
AD  - Department of Medical Oncology, The Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai, Shandong 264000, P.R. China.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Integrated Traditional Chinese and Western Medicine, The Affiliated 
      Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. 
      China.
FAU - Lv, Liping
AU  - Lv L
AD  - Department of Integrated Traditional Chinese and Western Medicine, The Affiliated 
      Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. 
      China.
FAU - Zou, Yong
AU  - Zou Y
AD  - Department of Integrated Traditional Chinese and Western Medicine, The Affiliated 
      Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. 
      China.
LA  - eng
PT  - Journal Article
DEP - 20180626
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6096140
OTO - NOTNLM
OT  - CO-releasing molecule-2
OT  - non-small cell lung cancer
OT  - nuclear factor-kappaB/toll-like receptor-4
OT  - phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin
EDAT- 2018/08/22 06:00
MHDA- 2018/08/22 06:01
PMCR- 2018/06/26
CRDT- 2018/08/22 06:00
PHST- 2017/11/22 00:00 [received]
PHST- 2018/06/06 00:00 [accepted]
PHST- 2018/08/22 06:00 [entrez]
PHST- 2018/08/22 06:00 [pubmed]
PHST- 2018/08/22 06:01 [medline]
PHST- 2018/06/26 00:00 [pmc-release]
AID - OL-0-0-9022 [pii]
AID - 10.3892/ol.2018.9022 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Sep;16(3):3223-3230. doi: 10.3892/ol.2018.9022. Epub 2018 Jun 
      26.